332 related articles for article (PubMed ID: 16563858)
21. Prediction of phenotypic susceptibility to antiretroviral drugs using physiochemical properties of the primary enzymatic structure combined with artificial neural networks.
Kjaer J; Høj L; Fox Z; Lundgren JD
HIV Med; 2008 Oct; 9(8):642-52. PubMed ID: 18631257
[TBL] [Abstract][Full Text] [Related]
22. Synonymous genetic polymorphisms within Brazilian human immunodeficiency virus Type 1 subtypes may influence mutational routes to drug resistance.
Dumans AT; Soares MA; Machado ES; Hué S; Brindeiro RM; Pillay D; Tanuri A
J Infect Dis; 2004 Apr; 189(7):1232-8. PubMed ID: 15031792
[TBL] [Abstract][Full Text] [Related]
23. Drug-resistance mutations in antiretroviral-naïve patients with established HIV-1 infection in Mexico.
Escoto-Delgadillo M; Vázquez-Valls E; Ramírez-Rodríguez M; Corona-Nakamura A; Amaya-Tapia G; Quintero-Pérez N; Panduro-Cerda A; Torres-Mendoza BM
HIV Med; 2005 Nov; 6(6):403-9. PubMed ID: 16268822
[TBL] [Abstract][Full Text] [Related]
24. Analysis of discrepancies in the interpretation of antiretroviral drug resistance results in HIV-1 infected patients of Basque Country, Spain.
Muñoz M; Carmona R; Pérez-Alvarez L; Cilla G; Suarez MD; Delgado E; Contreras G; Corral J; de Goicoetxea MJ; Medrano L; Lezaún MJ; Nájera R;
J Clin Virol; 2005 Jul; 33(3):224-9. PubMed ID: 15911444
[TBL] [Abstract][Full Text] [Related]
25. Human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns among treatment-naive patients in different stages of infection in Rio de Janeiro, Brazil.
Varella RB; Ferreira SB; de Castro MB; Zalis MG; Tavares MD
J Med Virol; 2007 Aug; 79(8):1033-9. PubMed ID: 17596836
[TBL] [Abstract][Full Text] [Related]
26. Human immunodeficiency virus-1 subtypes and antiretroviral drug resistance profiles among drug-naïve Brazilian blood donors.
Sá-Ferreira JA; Brindeiro PA; Chequer-Fernandez S; Tanuri A; Morgado MG
Transfusion; 2007 Jan; 47(1):97-102. PubMed ID: 17207236
[TBL] [Abstract][Full Text] [Related]
27. Genotypic analysis of the protease and reverse transcriptase of non-B HIV type 1 clinical isolates from naïve and treated subjects.
Monno L; Scudeller L; Brindicci G; Saracino A; Punzi G; Chirianni A; Lagioia A; Ladisa N; Lo Caputo S; Angarano G
Antiviral Res; 2009 Aug; 83(2):118-26. PubMed ID: 19549585
[TBL] [Abstract][Full Text] [Related]
28. Variability of the human immunodeficiency virus type 1 polymerase gene from treatment naïve patients in Accra, Ghana.
Sagoe KW; Dwidar M; Lartey M; Boamah I; Agyei AA; Hayford AA; Mingle JA; Arens MQ
J Clin Virol; 2007 Oct; 40(2):163-7. PubMed ID: 17827059
[TBL] [Abstract][Full Text] [Related]
29. Prevalence of HIV-1 polymerase gene mutations in pre-treated patients in Thailand.
Chantratita W; Jenwitheesuk E; Watitpun C; Pongthanapisith V; Vibhagool A; Leechawengwong M; Sookpranee M; Apairatana A
Southeast Asian J Trop Med Public Health; 2002 Mar; 33(1):80-4. PubMed ID: 12118466
[TBL] [Abstract][Full Text] [Related]
30. HIV-1 proteases from drug-naive West African patients are differentially less susceptible to protease inhibitors.
Kinomoto M; Appiah-Opong R; Brandful JA; Yokoyama M; Nii-Trebi N; Ugly-Kwame E; Sato H; Ofori-Adjei D; Kurata T; Barre-Sinoussi F; Sata T; Tokunaga K
Clin Infect Dis; 2005 Jul; 41(2):243-51. PubMed ID: 15983923
[TBL] [Abstract][Full Text] [Related]
31. Natural polymorphisms in the protease gene modulate the replicative capacity of non-B HIV-1 variants in the absence of drug pressure.
Holguín A; Suñe C; Hamy F; Soriano V; Klimkait T
J Clin Virol; 2006 Aug; 36(4):264-71. PubMed ID: 16765636
[TBL] [Abstract][Full Text] [Related]
32. Analysis of drug resistance-associated mutations in treatment-naïve individuals infected with different genetic forms of HIV-1 circulating in countries of the former Soviet Union.
Vázquez de Parga E; Rakhmanova A; Pérez-Alvarez L; Vinogradova A; Delgado E; Thomson MM; Casado G; Sierra M; Muñoz M; Carmona R; Vega Y; Contreras G; Medrano L; Osmanov S; Nájera R
J Med Virol; 2005 Nov; 77(3):337-44. PubMed ID: 16173024
[TBL] [Abstract][Full Text] [Related]
33. Analysis of the diversity of the HIV-1 pol gene and drug resistance associated changes among drug-naïve patients in Burkina Faso.
Tebit DM; Sangaré L; Tiba F; Saydou Y; Makamtse A; Somlare H; Bado G; Kouldiaty BG; Zabsonre I; Yameogo SL; Sathiandee K; Drabo JY; Kräusslich HG
J Med Virol; 2009 Oct; 81(10):1691-701. PubMed ID: 19697403
[TBL] [Abstract][Full Text] [Related]
34. Prevalence of drug resistance-related polymorphisms in treatment-naive individuals infected with nonsubtype B HIV type 1 in Cameroon.
Youngpairoj AS; Alemnji GA; Eno LT; Lyonga EJ; Eloundou MA; Shanmugam V; Mpoudi EN; Folks TM; Kalish ML; Pieniazek D; Fonjungo PN
AIDS Res Hum Retroviruses; 2012 Jul; 28(7):675-84. PubMed ID: 21923557
[TBL] [Abstract][Full Text] [Related]
35. Drug resistant mutations detected by genotypic drug resistance testing in patients failing therapy in clade C HIV-1 infected individuals from India.
Kandathil AJ; Kannangai R; Verghese VP; Pulimood SA; Rupali P; Sridharan G; Grant P; Pillay D; Abraham OC
Indian J Med Microbiol; 2009; 27(3):231-6. PubMed ID: 19584504
[TBL] [Abstract][Full Text] [Related]
36. High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients.
Masciotra S; Garrido C; Youngpairoj AS; McNulty A; Zahonero N; Corral A; Heneine W; de Mendoza C; García-Lerma JG
AIDS; 2007 Nov; 21(18):2503-11. PubMed ID: 18025887
[TBL] [Abstract][Full Text] [Related]
37. Genotypic resistance profiles in antiretroviral-naive HIV-1 infections before and after initiation of first-line HAART: impact of polymorphism on resistance to therapy.
Sukasem C; Churdboonchart V; Sukeepaisarncharoen W; Piroj W; Inwisai T; Tiensuwan M; Chantratita W
Int J Antimicrob Agents; 2008 Mar; 31(3):277-81. PubMed ID: 18182278
[TBL] [Abstract][Full Text] [Related]
38. Characterization of drug-resistance mutations in HIV-1 isolates from non-HAART and HAART treated patients in Burkina Faso.
Nadembega WM; Giannella S; Simpore J; Ceccherini-Silberstein F; Pietra V; Bertoli A; Pignatelli S; Bellocchi MC; Nikiema JB; Cappelli G; Bere A; Colizzi V; Perno CP; Musumeci S
J Med Virol; 2006 Nov; 78(11):1385-91. PubMed ID: 16998878
[TBL] [Abstract][Full Text] [Related]
39. Absence of genotypic drug resistance and presence of several naturally occurring polymorphisms of human immunodeficiency virus-1 CRF06_cpx in treatment-naive patients in Estonia.
Avi R; Huik K; Sadam M; Karki T; Krispin T; Ainsalu K; Paap P; Schmidt J; Nikitina N; Lutsar I
J Med Virol; 2009 Jun; 81(6):953-8. PubMed ID: 19382254
[TBL] [Abstract][Full Text] [Related]
40. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.
Witvrouw M; Pannecouque C; Switzer WM; Folks TM; De Clercq E; Heneine W
Antivir Ther; 2004 Feb; 9(1):57-65. PubMed ID: 15040537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
